Skip to main content

WPI 2357 Pill - yellow capsule/oblong, 16mm

Pill with imprint WPI 2357 is Yellow, Capsule/Oblong and has been identified as Topiramate Extended-Release 50 mg. It is supplied by Teva Pharmaceuticals USA, Inc.

Topiramate is used in the treatment of Migraine Prevention; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 50 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2357

Topiramate extended-release 50 mg WPI 2357

Topiramate Extended-Release

Imprint
WPI 2357
Strength
50 mg
Color
Yellow
Size
16.00 mm
Shape
Capsule/Oblong
Availability
Prescription only
Drug Class
Carbonic anhydrase inhibitor anticonvulsants
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Teva Pharmaceuticals USA, Inc.
National Drug Code (NDC)
00480-2357

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.